Dexmedetomidine Sedation in Children With Respiratory Morbidities

CompletedOBSERVATIONAL
Enrollment

19

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Respiratory Morbidity
Interventions
DRUG

Dexmedetomidine

Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg-1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg-1•h-1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg-1•h-1. In addition, propofol 0.5 mg.kg-1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.

Trial Locations (1)

1090

Universitair Ziekenhuis Brussel, Brussels

All Listed Sponsors
lead

Universitair Ziekenhuis Brussel

OTHER

NCT02555605 - Dexmedetomidine Sedation in Children With Respiratory Morbidities | Biotech Hunter | Biotech Hunter